Search the NeLM

Medicines A-Z
Find key information about medicines by name (prototype)
Denosumab for osteoporosis

Original article by: Alexandra Denby

Source: London New Drugs Group

Keywords: denosumab, osteoporosis

Date published: 03/06/2010 12:06

Summary
by: Alexandra Denby
  • Denosumab is a human monoclonal antibody that targets and binds with high affinity and specificity to RANK ligand (RANKL), preventing activation of the RANK receptor, which is found on osteoclast precursors and osteoclasts.
  • Denosumab should be administered by an individual who has been adequately trained in sub-cutaneous injection technique.  Denosumab is administered twice a year by sub-cutaneous injection.
  • Denosumab was launched in the UK in May 2010  for the treatment of osteoporosis in post-menopausal women at increased risk of fractures, and bone loss associated with men who are receiving hormone ablation therapy for prostate cancer and who are at risk of fractures.

    •  

    Denosumab_May_2010.pdf

    Preview your comment

    Add new comment

    Comment text:

    Comments

    There are no comments yet. You could be the first! You must be Logged In to comment.
    Back